Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Search
About Us
Sign in
Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Products
WEEKLY
FOCUS
ALPHA
Japanese chemical industry news
27 May 2026
Toray and PTT Global Chemical establish 100% bio-based nylon 66 production
End-to-end process converts cassava pulp to bio-muconic to bio-adipic acid and lab-polymerized 100% bio-based nylon 66. Pilot: 5 t/day glucose, 50 m³ fermenter. FY2028 target.
27 May 2026
Sumitomo Corporation and Gresham House to develop 694 MW UK BESS portfolio
JV will fund five utility-scale BESS projects with phased buildout (first three starting this fiscal year), expanding capacity and improving grid resilience.
27 May 2026
AkzoNobel to file SEC F-4 for Axalta merger; rejects Nippon Paint/Sherwin-Williams cash offer
Boards said the proposal undervalued the company, lacked regulatory/divestment certainty and failed to protect stakeholders; they unanimously back the planned merger and will provide updates.
27 May 2026
Mitsui Chemicals’ mass-balance biomass plastics adopted for Toshiba molded transformers
Mass-balance biomass plastics used in molded transformer parts and coils, compliant with 2026 Top Runner efficiency rules, support carbon-neutral value chains while matching petroleum performance.
27 May 2026
Asahi Kasei Life Science licenses Noguchi Institute’s precision ADC technology
Novel ADC modality enables precise DAR and attachment-site control for single- and dual-payload ADCs, improving predictability of efficacy/safety; will be commercialized and co-developed.
27 May 2026
Mitsubishi Chemical to Discontinue Certain Epoxy Resins at Tokai Plant
Some epoxy grades (BPA, BPF, and related formulations) will cease around Sep 30, 2027 due to aging equipment and weak market; certain items may be outsourced while focus shifts to semiconductor resins.
How does the Japanese chemical industry perform?
Find out with
chemXplore Alpha
Learn more
26 May 2026
WACKER sells 2.1 million Siltronic shares, raising €188 million
Placed at €89.35 each (7% of capital), reducing stake to ~24%; private accelerated bookbuild to qualified/institutional investors; proceeds to strengthen finances and fund growth.
26 May 2026
AGC Biologics Starts NN4101 Bispecific Antibody Development and GMP Production
With Novelty Nobility, moves Copenhagen cell‑line/MCB work to GMP manufacturing in Chiba from May 2026. Targets retinal neovascular disease; global cGMP network enables tech transfer.
26 May 2026
Chugai wins Imperial Invention Prize for recycling antibody technology
Recycling antibody tech uses pH‑dependent binding so one antibody binds multiple targets, increasing sustained efficacy, allowing lower doses, subcutaneous administration and longer dosing intervals.
25 May 2026
AGC opens DX Innovation Hub at IIT Hyderabad
R&D and talent-development base for DX - integrates IT and manufacturing expertise, advances AI projects (anomaly detection, demand forecasting) and enables global deployment of skills and tech.
22 May 2026
Eli Lilly's Foundayo (orforglipron) reduces body weight up to 13% in adults 65+
Once-daily oral orforglipron can be taken any time without food/water restrictions; showed significant 72-week weight loss across ages and diabetes status; safety consistent; GI AEs common.
21 May 2026
Shofu, Tosoh, Mitsui Chemicals, Orbray launch zirconia dental-waste recycling project
Verification project to recycle zirconia dental milling waste into regenerated raw material and remanufactured blocks for reuse; practical use targeted by FY2028 with dental labs.
20 May 2026
bp signs three PSCs in Indonesia
Signed three PSCs in Indonesia: Bintuni and Drawa near Tangguh LNG (potential short‑cycle development) and Barong in East Java, raising participation to 11 blocks; part of 2025 bidding round.
20 May 2026
Mitsui Chemicals Included in Dow Jones Best‑in‑Class Asia Pacific Index for 8th Year
DJBiC evaluates ESG across ~600 Asia‑Pacific firms; 162 companies (76 Japanese) selected in 2025. Also in FTSE4Good, MSCI ESG Leaders and six GPIF indices. Highlights Blue Value (env.) and Rose Value.
19 May 2026
Novo Nordisk: Semaglutide shows hepatic safety and efficacy in MASH
ESSENCE subgroup analyses (menopause, Japanese) and real-world data show broad benefit across populations, highlight severe underdiagnosis, reduced quality of life and rising healthcare costs
19 May 2026
Takeda: Jury verdict in AMITIZA antitrust case; FY2025 results to be revised
Jury awarded USD 884,943,990 in single damages in AMITIZA antitrust trial; wholesaler/retailer sums subject to trebling. Will appeal, assess provision and revise FY2025 filings; minimal FY2026 impact.
18 May 2026
Boehringer Ingelheim's JASCAYD (nerandomilast) approved in Japan for IPF and PPF
First oral PDE4B inhibitor shows slowed FVC decline in FIBRONEER Phase III; pooled analysis showed 59% nominal death reduction. Common AE: diarrhea; EU/UK reviews ongoing.
18 May 2026
Asahi Kasei Starts Phase III Trial of Teribone for High‑Risk Osteoporosis
Phase III in Japan will evaluate extended teriparatide acetate treatment beyond 24 months for severe osteoporosis patients at high fracture risk, assessing efficacy and safety of continued dosing.
18 May 2026
Asahi Kasei Therapeutics starts Phase III trial of Teribone (teriparatide) for high‑risk osteoporosis
Domestic Phase III trial to assess extended therapy beyond 24 months for patients with severe osteoporosis at high fracture risk; evaluates efficacy and safety of continued treatment.
18 May 2026
Teijin Frontier and Asahi Kasei Advance form TA Frontier
Merged firm launches Oct 1, 2026; ownership split 80/20. It combines materials technologies and marketing across textiles, industrial, building and resins for sustainable growth.
18 May 2026
Chugai’s Alecensa Gets World-First Tumor‑Agnostic Approval for ALK‑Positive Solid Tumors
Japan approves tumor‑agnostic ALK inhibitor for ALK‑fusion solid tumors including pediatrics. TACKLE Phase II showed 70–76% response in ALK‑fusion cases; safety consistent. FoundationOne CDx approved.
18 May 2026
Chugai: MHLW approves FoundationOne CDx as Alecensa companion diagnostic for ALK‑positive solid tumors
TACKLE Phase II supported Alecensa's efficacy/safety, enabling a partial marketing-authorization change; FoundationOne CDx expands tumor-agnostic genomic profiling and treatment options.
18 May 2026
GSK’s Arexvy gains expanded approval in Japan for at‑risk adults 18–59
Approval now explicitly includes immunocompromised adults; Phase IIIb showed non‑inferior immune response versus older adults and a safety profile consistent with prior trials.
14 May 2026
OrganOx appoints Naoya Iwata CEO & President
Effective June 1, 2026, he brings 20+ years at Terumo in sales, strategy and business development, including Chief of Staff experience, to scale commercial growth and NMP adoption.
14 May 2026
LanzaTech Q1 2026 Results
Q1: closed $30M equity raises (plus up to $20M option), going‑concern resolved; revenue $12M; net loss narrowed to $14.7M; Adj. EBITDA loss $7.9M; OpEx down 59%; India, UK, Japan milestones.
14 May 2026
Chugai, Nippon Shinyaku file Gazyva (obinutuzumab) for idiopathic nephrotic syndrome
Phase III INShore showed improved sustained remission and steroid reduction versus MMF; no new safety signals, supporting a regulatory application.
12 May 2026
Asahi Kasei to Realign Material Supply by FY2030
Streamline Mizushima Works by FY2030; no immediate supply impact. Exiting low-margin derivative businesses (¥116.2bn 2025) to boost margins, free capital for pharma, healthcare, homes, electronics.
12 May 2026
Asahi Kasei, Mitsui Chemicals and Mitsubishi Chemical agree 45/45/10 equity split for western Japan ethylene JV
Plan to integrate western Japan ethylene assets: close Mizushima plant by 2030 and consolidate operations at a single site to decarbonize, optimize capacity and strengthen competitiveness.
11 May 2026
GSK partners with Sino Biopharmaceutical (CTTQ) for exclusive China launch of bepirovirsen
Potential first-in-class CHB treatment under priority review in China; deal provides access to 5,000+ medical centres at launch, local import/distribution, hospital access and initial 5.5-yr supply.
11 May 2026
Sumitomo Corporation: Noirmoutier 500 MW Offshore Wind Farm in France Begins Commercial Operation
Construction complete; commercial operation started. 12 km offshore; ~25‑yr life. Annual output ≈ supply for 800k users. Power sold under long‑term fixed‑price PPA; financed via syndicated loan.
Next →
